Morgan Stanley Reiterates Overweight Rating on IDEXX Laboratories, Inc. (IDXX)

Market Context

IDEXX Laboratories, Inc. operates in the Healthcare sector. The stock currently trades at $672.04 with a market capitalization of $56.5B. The stock has declined 6.0% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for IDEXX Laboratories, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for IDEXX Laboratories, Inc.

Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 03, 2026	UBS	Neutral	N/A
Nov 03, 2026	Morgan Stanley	Overweight	N/A
Oct 27, 2026	UBS	Neutral	N/A
Oct 16, 2026	JP Morgan	Overweight	N/A
Oct 12, 2026	Keybanc	Sector Weight	N/A

Related Tools: Analyst Ratings Dashboard | View IDXX Stock Page